"Everyone knows ADXS is high-risk. The salient point you’re omitting is that NEO may be enough, all by itself, to warrant a much higher valuation." ... It will be many, many years before NEO is either proved to be the real deal with FDA approval or another ADXS dud. ADXS share price has collapsed from $16 since Amgen partnered for NEO. More mass dilution & another reverse split coming next year. Berlin is another in the long list of previous ADXS incompetent CEO failures.
News 
Market Data 
Discover 
